eligibility_summary
Eligible: Those who received a BMS-manufactured gene-modified cell therapy (commercial or investigational without its own testing protocol, including non-conforming product) and have a BMS-qualified second primary malignancy. Exclude: those actively enrolled in a trial collecting samples/data, or anyone who has not received a BMS GMCT or lacks a qualifying second primary malignancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: Idecabtagene vicleucel (ide-cel) and lisocabtagene maraleucel (liso-cel), both autologous gene‑modified CAR T‑cell immunotherapies. Mechanisms of action: Patient T cells are engineered to express chimeric antigen receptors that recognize tumor antigens and, upon binding, activate T‑cell effector functions (cytokine release, cytolytic killing). Ide-cel targets BCMA, liso-cel targets CD19. Target cells/pathways: Ide-cel engages BCMA on malignant plasma cells in multiple myeloma, liso-cel engages CD19 on malignant B cells in NHL/CLL. Signaling through the CAR activates T‑cell cytotoxic pathways leading to apoptosis of BCMA+ or CD19+ cells. Study purpose: observational transgene assay of tumors from patients with a qualifying second primary malignancy after these therapies.